Skip to main content

Starling Oncology, Inc 8-K, filed Nov 12, 2026

Starling Oncology, Inc. (STLN)

8-K 2026-11-12 For: 2026-11-12
View Original
Added on November 12, 2026

About this 8-K

Starling Oncology, Inc filed this 8-K on November 12, 2026.

Starling Oncology forecasts FY26 revenue of $650 – 660M and Adjusted EBITDA of $4 – 6M; 3Q26 revenue increased 24% YoY to $170M, with Adjusted EBITDA of $3.4M. AI summary

Items reported

  • Item 7.01: Regulation FD disclosure
  • Item 9.01: Financial statements and exhibits